Abstract
The yeast Saccharomyces boulardii is a biotherapeutic agent used for the prevention and treatment of several gastrointestinal diseases, such as diarrhoea caused by Clostridium difficile, in addition to the antibiotic therapy. In this study we report a case of Saccharomyces cerevisiae fungemia in a patient with Clostridium difficile-associated diarrhoea (CDAD) treated orally with S. boulardii in association with vancomycin. The identification of the S. cerevisiae was confirmed by molecular technique. Fungemia is a rare, but a serious complication to treatment with probiotics. We believe it is important to remind the clinicians of this risk when prescribing probiotics, especially to immunocompromised patients. Copyright © by BIOLIFE, s.a.s.
Author supplied keywords
Cite
CITATION STYLE
Santino, I., Alari, A., Bono, S., Teti, E., Marangi, M., Bernardini, A., … Teggi, A. (2014). Saccharomyces cerevisiae fungemia, a possible consequence of the treatment of Clostridium difficile colitis with a probioticum. International Journal of Immunopathology and Pharmacology, 27(1), 143–146. https://doi.org/10.1177/039463201402700120
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.